<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article article-type="letter"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Leukemia</journal-id><journal-id journal-id-type="iso-abbrev">Leukemia</journal-id><journal-title-group><journal-title>Leukemia</journal-title></journal-title-group><issn pub-type="ppub">0887-6924</issn><issn pub-type="epub">1476-5551</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">22810506</article-id><article-id pub-id-type="pmc">3567236</article-id><article-id pub-id-type="pii">leu2012209</article-id><article-id pub-id-type="doi">10.1038/leu.2012.209</article-id><article-categories><subj-group subj-group-type="heading"><subject>Letter to the Editor</subject></subj-group></article-categories><title-group><article-title>The use of individualized tumor response testing in treatment selection: second randomization results from the LRF CLL4 trial and the predictive value of the test at trial entry</article-title><alt-title alt-title-type="running">Letter to the Editor</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Matutes</surname><given-names>E</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="author-notes" rid="note1"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Bosanquet</surname><given-names>A G</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="author-notes" rid="note1"><sup>4</sup></xref><xref ref-type="author-notes" rid="note2"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Wade</surname><given-names>R</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Richards</surname><given-names>S M</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Else</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Catovsky</surname><given-names>D</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="caf1">*</xref></contrib><aff id="aff1"><label>1</label><institution>Haemato-Oncology Research Unit, The Institute of Cancer Research</institution>, Sutton, <country>UK</country></aff><aff id="aff2"><label>2</label><institution>Bath Cancer Research, Royal United Hospital</institution>, Bath, <country>UK</country></aff><aff id="aff3"><label>3</label><institution>Clinical Trial Service Unit</institution>, Oxford University, Oxford, <country>UK</country></aff></contrib-group><author-notes><corresp id="caf1"><label>*</label>E-mail: <email>Daniel.catovsky@icr.ac.uk</email></corresp><fn fn-type="present-address" id="note1"><label>4</label><p>These authors are joint first authors.</p></fn><fn fn-type="present-address" id="note2"><label>5</label><p>Current address: TEST Laboratories, Bath, UK. Bath Cancer Research has closed.</p></fn></author-notes><pub-date pub-type="ppub"><month>02</month><year>2013</year></pub-date><pub-date pub-type="epreprint"><day>19</day><month>07</month><year>2012</year></pub-date><pub-date pub-type="epub"><day>10</day><month>08</month><year>2012</year></pub-date><volume>27</volume><issue>2</issue><fpage>507</fpage><lpage>510</lpage><permissions><copyright-statement>Copyright &#x000a9; 2013 Macmillan Publishers Limited</copyright-statement><copyright-year>2013</copyright-year><copyright-holder>Macmillan Publishers Limited</copyright-holder><license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0/"><!--author-paid--><license-p>This work is licensed under the Creative Commons Attribution-NonCommercial-No Derivative Works 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/</license-p></license></permissions></article-meta></front><body><p>The choice of treatment according to <italic>in vitro</italic> drug response testing was developed for chronic lymphocytic leukemia (CLL) as the Differential Staining Cytotoxicity assay.<sup><xref ref-type="bibr" rid="bib1">1</xref></sup> This demonstrated that fludarabine-test-resistant patients treated with fludarabine had a poorer response rate and worse median survival than fludarabine-test-sensitive patients.<sup><xref ref-type="bibr" rid="bib2">2</xref></sup> A simplified method, the tumor response to anti-neoplastic compounds (TRAC) assay, was developed and its value documented in CLL patients.<sup><xref ref-type="bibr" rid="bib3">3</xref></sup></p><p>We report the largest study in patients entered into a randomized trial, in three contexts:
<list list-type="order"><list-item><p>As a randomized variable in nonresponders and relapsed patients to assess its value in the choice of second-line therapy.</p></list-item><list-item><p>Assessing <italic>in vitro</italic> sensitivity to therapy received, as a prognostic variable after second-line treatment.</p></list-item><list-item><p>At study entry, to ascertain whether the <italic>in vitro</italic> sensitivity to treatment received could predict outcome, and to assess correlation with other prognostic factors.</p></list-item></list></p><p>The LRF CLL4 trial was a multicenter study including 777 CLL patients requiring treatment, randomized from 1999&#x02013;2004 to receive chlorambucil, or fludarabine alone or with cyclophosphamide. Response rates, progression-free survival (PFS), overall survival (OS), and the prognostic impact of clinical and biological variables, have been published.<sup><xref ref-type="bibr" rid="bib4">4</xref>, <xref ref-type="bibr" rid="bib5">5</xref></sup> A second randomization (2000&#x02013;2008) was incorporated for patients who were nonresponders, progressed while on first-line treatment, or relapsed within a year of remission. The trial was approved by a UK multicenter research ethics committee.</p><p>The TRAC assay was performed on blood samples. At trial entry, the result was not available to patients or physicians. The second randomization, using a new sample, was between &#x02018;TRAC-assay-guided' and &#x02018;protocol-guided' therapy. Randomization was balanced with respect to age, gender, disease status and planned treatment. Before second randomization, physicians specified what treatment they planned to give. TRAC assay reports were only sent to the physician for patients allocated to assay-guided therapy. TRAC methodology was previously described.<sup><xref ref-type="bibr" rid="bib3">3</xref></sup> Drugs tested were chlorambucil, cyclophosphamide (mafosfamide <italic>in vitro</italic>), methyl-prednisolone, prednisolone, vincristine, doxorubicin, mitoxantrone, cladribine, fludarabine and pentostatin; and the drug concentrations lethal for 90&#x00025; of cells (LC<sub>90</sub>s) were determined. The report sent to doctors showed drug sensitivities as a drug sensitivity index&#x02014;a percentage rank of LC<sub>90</sub>s whereby 0&#x00025; indicated the most resistant patient and 90&#x00025; indicated very sensitive.<sup><xref ref-type="bibr" rid="bib3">3</xref></sup> For analysis, trial entry LC<sub>90</sub> results were compared with response. Cutoffs were determined for sensitive, intermediate and resistant. For drug combinations, all drugs needed to show resistance <italic>in vitro</italic> for the combination to be considered TRAC-resistant. For TRAC-sensitivity, at least one drug needed to show <italic>in vitro</italic> sensitivity. Patient response was assessed using the National Cancer Institute criteria. PFS was defined as the time from first randomization to relapse, progression or death. OS from randomization was the primary outcome. <italic>&#x003c7;</italic><sup>2</sup> was used for testing associations between categorical variables. Analyses of outcome used Kaplan&#x02013;Meier curves and log-rank comparisons between groups. Cox regression was used for multivariate analysis. The follow-up was up to 31st October 2010 (median follow-up from trial entry was 7 years 6 months; from second randomization 5 years 9 months). <italic>P</italic>-values were two-sided.</p><p>(1) At second randomization, 84 patients were allocated to protocol-guided and 84 patients to TRAC-assay-guided treatment. Most (73&#x00025;) had initially received chlorambucil; 40&#x00025; were nonresponders and 60&#x00025; had relapsed. There were no significant differences between the two groups regarding patient/disease characteristics (<xref ref-type="supplementary-material" rid="sup1">Supplementary Table 1</xref>). Fifty-two percent of physicians planned to give fludarabine as second-line treatment. The proportion of patients who did not receive the planned treatment did not differ significantly between the planned treatments (fludarabine 25&#x00025;, cyclophosphamide, doxorubicin, vincristine and prednisolone 47&#x00025;, fludarabine with cyclophosphamide&#x000b1;/&#x02212;rituximab or mitoxantrone 30&#x00025;). As expected, fewer TRAC-assay-guided patients received their planned treatment compared with protocol-guided (51 vs 83&#x00025;, <italic>P</italic>&#x0003c;0.0001). In the protocol-guided arm there was no difference in the proportion receiving their planned treatment by TRAC assay result (10/13 (77&#x00025;) TRAC-resistant vs 51/60 (85&#x00025;) TRAC nonresistant, <italic>P</italic>=0.5). In the TRAC-assay-guided arm 0/10 (0&#x00025;) of the TRAC-resistant patients received their planned treatment compared with 41/66 (62&#x00025;) TRAC nonresistant (<italic>P</italic>=0.0002) (<xref ref-type="supplementary-material" rid="sup1">Supplementary Table 2</xref>). This suggests that the report, when available, was used by the physicians to alter the planned treatment when drug resistance was indicated.</p><p>There were no significant differences between assay-guided vs protocol-guided in response rate (<xref ref-type="supplementary-material" rid="sup1">Supplementary Table 3</xref>) or OS (<xref ref-type="fig" rid="fig1">Figure 1a</xref>). However, survival at 1 year was better (<italic>P</italic>=0.04). Results were not altered if stratified by age, stage, gender or risk group.<sup><xref ref-type="bibr" rid="bib5">5</xref></sup> Within the TRAC-resistant subgroup there was no significant difference in OS between the randomized arms (odds ratio=1.04; 95&#x00025; confidence interval: 0.72&#x02013;1.49; <italic>P</italic>=0.8).</p><p>(2) No patient in the TRAC-assay-guided arm received a treatment to which they were resistant, compared with 17&#x00025; in the protocol-guided arm (<italic>P</italic>=0.0002). Patients with greater <italic>in vitro</italic> sensitivity to the given treatment were more likely to respond (sensitive 57/68 (84&#x00025;), intermediate 39/55 (71&#x00025;), resistant 5/10 (50&#x00025;)); (<italic>P</italic>(trend)=0.01), independently of the randomized arm. There was no significant difference in survival from second randomization by TRAC assay (sensitive/intermediate/resistant) to the given treatment, <italic>P</italic>(trend)=0.4 (<xref ref-type="fig" rid="fig1">Figure 1b</xref>); however, the 13 resistant patients appeared to fare worse than the others, odds ratio=1.75 (95&#x00025; confidence interval: 0.82&#x02013;3.72), <italic>P</italic>=0.2.</p><p>(3) At trial entry, the TRAC assay was performed in 544/777 randomized patients, and this group was broadly representative. Higher LC<sub>90</sub>s for fludarabine, chlorambucil and mafosfamide were associated with 17p deletion and 11q deletion and for chlorambucil and mafosfamide, but not fludarabine, with unmutated <italic>IGHV</italic> mutational status (<xref ref-type="supplementary-material" rid="sup1">Supplementary Table 4</xref>).</p><p>TRAC-assay-sensitivity was predictive of improved OS (<xref ref-type="fig" rid="fig1">Figure 1c</xref>). In univariate analyses, LC<sub>90</sub>s for fludarabine, chlorambucil and mafosfamide were statistically significant for both PFS and OS (<xref rid="tbl1" ref-type="table">Table 1</xref>). When the TRAC assay result was added to a multivariate OS model it was not significant (<italic>P</italic>=0.8). For PFS, the LC<sub>90</sub> for fludarabine added independent prognostic value (<italic>P</italic>=0.002), though the LC<sub>90</sub> for chlorambucil was of borderline significance (<italic>P</italic>=0.05) and for mafosfamide was nonsignificant. When including LC<sub>90</sub> results for both fludarabine and chlorambucil, only the fludarabine result was significant (<xref rid="tbl1" ref-type="table">Table 1</xref>).</p><p>Our results suggest that <italic>in vitro</italic> drug sensitivity correlates with patients' outcome. When considering all relapsed/refractory patients, there was an association between <italic>in vivo</italic> response and greater sensitivity by TRAC assay. PFS from second randomization was not measured, but survival at 1 year was significantly better in the TRAC-assay-guided arm&#x02014;a result which is of particular interest given that no chemotherapy-only protocol has been shown to increase OS.</p><p>Several studies have investigated the <italic>in vitro</italic> drug sensitivity of CLL cells<sup><xref ref-type="bibr" rid="bib2">2</xref>, <xref ref-type="bibr" rid="bib6">6</xref>, <xref ref-type="bibr" rid="bib7">7</xref>, <xref ref-type="bibr" rid="bib8">8</xref>, <xref ref-type="bibr" rid="bib9">9</xref>, <xref ref-type="bibr" rid="bib10">10</xref></sup> and its relationship with clinical and biological parameters.<sup><xref ref-type="bibr" rid="bib11">11</xref>, <xref ref-type="bibr" rid="bib12">12</xref>, <xref ref-type="bibr" rid="bib13">13</xref>, <xref ref-type="bibr" rid="bib14">14</xref></sup> These results suggested that <italic>in vitro</italic> drug sensitivity of CLL cells is independent of <italic>IGHV</italic> gene mutation status.<sup><xref ref-type="bibr" rid="bib11">11</xref>, <xref ref-type="bibr" rid="bib14">14</xref></sup> However, as expected from clinical experience, <italic>in vitro</italic> sensitivity to fludarabine and chlorambucil was lower in patients with <italic>ATM/TP53</italic> deletions<sup><xref ref-type="bibr" rid="bib13">13</xref>, <xref ref-type="bibr" rid="bib14">14</xref></sup> and higher in patients with low-beta-2 microglobulin, longer lymphocyte doubling-time and lack of <italic>TP53</italic> deletion.<sup><xref ref-type="bibr" rid="bib12">12</xref></sup> The <italic>in vitro</italic> prednisolone sensitivity of <italic>TP53</italic>-deleted cases correlated with the reported <italic>in vivo</italic> sensitivity.<sup><xref ref-type="bibr" rid="bib15">15</xref></sup> These studies reported only a small number of cases, with little information concerning the relationship between the <italic>in vitro</italic> and <italic>in vivo</italic> findings. Morabito <italic>et al.</italic>,<sup><xref ref-type="bibr" rid="bib9">9</xref></sup> using the MTT assay, concluded that <italic>in vitro</italic> testing for fludarabine predicted response. Castejon's study,<sup><xref ref-type="bibr" rid="bib12">12</xref></sup> using an <italic>in vitro</italic> apoptotic test in 50 patients, showed that sensitivity to fludarabine correlated with a clinical response but, unlike in our study, there was no correlation between <italic>in vitro</italic> sensitivity and <italic>in vivo</italic> response to chlorambucil.</p><p>Information on the significance of <italic>in vitro</italic> drug sensitivity assays in CLL is limited to a few nonrandomized studies.<sup><xref ref-type="bibr" rid="bib2">2</xref>, <xref ref-type="bibr" rid="bib3">3</xref></sup> The main findings were a correlation between <italic>in vitro</italic> and <italic>in vivo</italic> sensitivity to fludarabine, which translated into longer survival for the fludarabine-sensitive group,<sup><xref ref-type="bibr" rid="bib2">2</xref></sup> and a lack of <italic>in vitro</italic> cross-resistance between fludarabine and pentostatin, suggesting that pentostatin could be a salvage drug in fludarabine-resistant patients.<sup><xref ref-type="bibr" rid="bib3">3</xref></sup></p><p>The present study is the only one that analyzes the value of the <italic>in vitro</italic> drug assay in untreated CLL patients entered into a randomized clinical trial, and in whom clinical and biological prognostic factors were considered. <italic>In vitro</italic> drug resistance correlated with the presence of 17p and 11q deletion, as documented in other small studies,<sup><xref ref-type="bibr" rid="bib13">13</xref>, <xref ref-type="bibr" rid="bib14">14</xref></sup> but also with unmutated <italic>IGHV</italic> genes. The TRAC assay LC<sub>90</sub>(fludarabine), together with 17p and 11q deletion and <italic>IGHV</italic> gene mutation status was an independent variable predicting PFS. Although the TRAC assay result was associated with OS in univariate analysis, it was not significant in multivariate analysis. This might be because most relapsed and refractory patients had been treated with chlorambucil and were rescued with alternative therapies.</p><p>In summary, the TRAC assay may be of value in practice, particularly in untreated patients who are unfit for intensive regimens and for whom treatment with chlorambucil or fludarabine is planned. The use of these agents in patients with <italic>in vitro</italic> drug resistance predicts nonresponse. In the relapse setting, short-term survival may be improved, while further studies including new agents (for example, bendamustine, lenalidomide) in the panel of drugs tested may give additional information on the clinical value of testing. At diagnosis, the TRAC assay provided prognostic information additional to other known factors.</p></body><back><ack><p>The LRF CLL4 trial was supported by a core grant from Leukaemia &#x00026; Lymphoma Research. The CTSU received research support from the Medical Research Council and Cancer Research UK. TRAC assay results were supported by Leukaemia &#x00026; Lymphoma Research and Bath Cancer Research. Other laboratory studies were supported by an educational grant from Schering Health Care (UK) and Schering AG (Germany). ME was supported by the Arbib Foundation. Prof David Oscier performed the laboratory tests for other prognostic factors.</p></ack><fn-group><fn><p><xref ref-type="supplementary-material" rid="sup1">Supplementary Information</xref> accompanies the paper on the Leukemia website (http://www.nature.com/leu)</p></fn></fn-group><notes><p>The authors declare no conflict of interest.</p></notes><ref-list><ref id="bib1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bosanquet</surname><given-names>AG</given-names></name><name><surname>Burlton</surname><given-names>AR</given-names></name><name><surname>Bell</surname><given-names>PB</given-names></name><name><surname>Harris</surname><given-names>AL</given-names></name></person-group><article-title><italic>Ex vivo</italic> cytotoxic drug evaluation by DiSC assay to expedite identification of clinical targets: results with 8-chloro-cAMP</article-title><source>Br J Cancer</source><year>1997</year><volume>76</volume><fpage>511</fpage><lpage>518</lpage><pub-id pub-id-type="pmid">9275029</pub-id></mixed-citation></ref><ref id="bib2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bosanquet</surname><given-names>AG</given-names></name><name><surname>Johnson</surname><given-names>SA</given-names></name><name><surname>Richards</surname><given-names>SM</given-names></name></person-group><article-title>Prognosis for fludarabine therapy of chronic lymphocytic leukaemia based on <italic>ex vivo</italic> drug response by DiSC assay</article-title><source>Br J Haematol</source><year>1999</year><volume>106</volume><fpage>71</fpage><lpage>77</lpage><pub-id pub-id-type="pmid">10444165</pub-id></mixed-citation></ref><ref id="bib3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bosanquet</surname><given-names>AG</given-names></name><name><surname>Richards</surname><given-names>SM</given-names></name><name><surname>Wade</surname><given-names>R</given-names></name><name><surname>Else</surname><given-names>M</given-names></name><name><surname>Matutes</surname><given-names>E</given-names></name><name><surname>Dyer</surname><given-names>MJS</given-names></name><etal/></person-group><article-title>Drug cross-resistance and therapy-induced resistance in chronic lymphocytic leukaemia by an enhanced method of individualised tumour response testing</article-title><source>Br J Haematol</source><year>2009</year><volume>146</volume><fpage>384</fpage><lpage>395</lpage><pub-id pub-id-type="pmid">19552723</pub-id></mixed-citation></ref><ref id="bib4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Catovsky</surname><given-names>D</given-names></name><name><surname>Richards</surname><given-names>S</given-names></name><name><surname>Matutes</surname><given-names>E</given-names></name><name><surname>Oscier</surname><given-names>D</given-names></name><name><surname>Dyer</surname><given-names>MJS</given-names></name><name><surname>Bezares</surname><given-names>RF</given-names></name><collab>on behalf of the UK National Cancer Research Institute (NCRI) Haematological Oncology Clinical Studies Group and NCRI Chronic Lymphocytic Leukaemia Working Group</collab><etal/></person-group><article-title>Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial</article-title><source>Lancet</source><year>2007</year><volume>370</volume><fpage>230</fpage><lpage>239</lpage><pub-id pub-id-type="pmid">17658394</pub-id></mixed-citation></ref><ref id="bib5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oscier</surname><given-names>D</given-names></name><name><surname>Wade</surname><given-names>R</given-names></name><name><surname>Davis</surname><given-names>Z</given-names></name><name><surname>Morilla</surname><given-names>A</given-names></name><name><surname>Best</surname><given-names>G</given-names></name><name><surname>Richards</surname><given-names>S</given-names></name><etal/></person-group><article-title>for the UK National Cancer Research Institute (NCRI) Chronic Lymphocytic Leukaemia Working Group. Biological risk factors identify 3 risk groups in the LRF CLL4 trial independent of treatment allocation</article-title><source>Hematologica</source><year>2010</year><volume>95</volume><fpage>1705</fpage><lpage>1712</lpage></mixed-citation></ref><ref id="bib6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silber</surname><given-names>R</given-names></name><name><surname>Degar</surname><given-names>B</given-names></name><name><surname>Costin</surname><given-names>D</given-names></name><name><surname>Newcomb</surname><given-names>EW</given-names></name><name><surname>Mani</surname><given-names>M</given-names></name><name><surname>Rosemberg</surname><given-names>CR</given-names></name><etal/></person-group><article-title>Chemosensitivity of lymphocytes from patients with B-cell chronic lymphocytic leukemia to chlorambucil, fludarabine and captothecin analogs</article-title><source>Blood</source><year>1994</year><volume>84</volume><fpage>3440</fpage><lpage>3446</lpage><pub-id pub-id-type="pmid">7949099</pub-id></mixed-citation></ref><ref id="bib7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hilgenfeld</surname><given-names>E</given-names></name><name><surname>Nauf</surname><given-names>WU</given-names></name><name><surname>Thiel</surname><given-names>E</given-names></name></person-group><article-title>Cytotoxicity of fludarabine <italic>in vitro</italic> cannot predict outcome in patients with advanced stage B-cell chronic lymphocytic leukemia (B-CLL)</article-title><source>Leukemia</source><year>1995</year><volume>9</volume><fpage>541</fpage><lpage>546</lpage></mixed-citation></ref><ref id="bib8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bromidge</surname><given-names>TJ</given-names></name><name><surname>Turner</surname><given-names>DL</given-names></name><name><surname>Howe</surname><given-names>DJ</given-names></name><name><surname>Johnson</surname><given-names>SA</given-names></name><name><surname>Rule</surname><given-names>SAJ</given-names></name></person-group><article-title><italic>In vitro</italic> chemosensitivity of chronic lymphocytic leukemia to purine analogues-correlation with clinical course</article-title><source>Leukemia</source><year>1998</year><volume>12</volume><fpage>1230</fpage><lpage>1235</lpage><pub-id pub-id-type="pmid">9697877</pub-id></mixed-citation></ref><ref id="bib9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morabito</surname><given-names>F</given-names></name><name><surname>Stelitano</surname><given-names>C</given-names></name><name><surname>Callea</surname><given-names>I</given-names></name><name><surname>Dattola</surname><given-names>A</given-names></name><name><surname>Console</surname><given-names>G</given-names></name><name><surname>Puci</surname><given-names>G</given-names></name><etal/></person-group><article-title><italic>In vitro</italic> drug-induced cytotoxicity predicts clinical response to fludarabine in B-cell chronic lymphocytic leukemia</article-title><source>Br J Haematol</source><year>1998</year><volume>102</volume><fpage>528</fpage><lpage>531</lpage><pub-id pub-id-type="pmid">9695969</pub-id></mixed-citation></ref><ref id="bib10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bellosillo</surname><given-names>B</given-names></name><name><surname>Villamor</surname><given-names>N</given-names></name><name><surname>Colomer</surname><given-names>D</given-names></name><name><surname>Pons</surname><given-names>G</given-names></name><name><surname>Montserrat</surname><given-names>E</given-names></name><name><surname>Gil</surname><given-names>J</given-names></name></person-group><article-title><italic>In vitro</italic> evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukemia</article-title><source>Blood</source><year>1999</year><volume>94</volume><fpage>2836</fpage><lpage>2843</lpage><pub-id pub-id-type="pmid">10515887</pub-id></mixed-citation></ref><ref id="bib11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kivekas</surname><given-names>I</given-names></name><name><surname>Tobin</surname><given-names>G</given-names></name><name><surname>Thunberg</surname><given-names>U</given-names></name><name><surname>Vilpo</surname><given-names>L</given-names></name><name><surname>Sundstrom</surname><given-names>C</given-names></name><name><surname>Rosenquist</surname><given-names>R</given-names></name><etal/></person-group><article-title><italic>Ex vivo</italic> drug and irradiation sensitivities in hypermutated and unmutated forms of chronic lymphocytic leukemia cells</article-title><source>Leuk Res</source><year>2003</year><volume>27</volume><fpage>337</fpage><lpage>341</lpage><pub-id pub-id-type="pmid">12531225</pub-id></mixed-citation></ref><ref id="bib12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castejon</surname><given-names>R</given-names></name><name><surname>Yebra</surname><given-names>M</given-names></name><name><surname>Citroes</surname><given-names>MJ</given-names></name><name><surname>Villareal</surname><given-names>M</given-names></name><name><surname>Garcia-Marco</surname><given-names>JA</given-names></name><name><surname>Vargas</surname><given-names>JA</given-names></name></person-group><article-title>Drug induction apoptosis assay as predictive value of chemotherapy response in patients with B-cell chronic lymphocytic leukemia</article-title><source>Leuk Lymphoma</source><year>2009</year><volume>50</volume><fpage>593</fpage><lpage>603</lpage><pub-id pub-id-type="pmid">19373658</pub-id></mixed-citation></ref><ref id="bib13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhong</surname><given-names>Y</given-names></name><name><surname>Bakke</surname><given-names>AC</given-names></name><name><surname>Fan</surname><given-names>G</given-names></name><name><surname>Braziel</surname><given-names>RM</given-names></name><name><surname>Gatter</surname><given-names>KM</given-names></name><name><surname>Leis</surname><given-names>JF</given-names></name><etal/></person-group><article-title>Drug resistance in B-cell chronic lymphocytic leukemia: predictable by <italic>in vitro</italic> evaluation with a multiparameter flow cytometric cytotoxicity assay</article-title><source>Cytometry B Clin Cytom</source><year>2007</year><volume>72</volume><fpage>189</fpage><lpage>195</lpage><pub-id pub-id-type="pmid">17226861</pub-id></mixed-citation></ref><ref id="bib14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lindhagen</surname><given-names>E</given-names></name><name><surname>Norberg</surname><given-names>M</given-names></name><name><surname>Kanduri</surname><given-names>M</given-names></name><name><surname>Tobin</surname><given-names>G</given-names></name><name><surname>Saisanen</surname><given-names>L</given-names></name><name><surname>Aberg</surname><given-names>M</given-names></name><etal/></person-group><article-title><italic>In vitro</italic> activity of 20 agents in different prognostic subgroups of chronic lymphocytic leukemia-rolipram and prednisolone active in cells from patients with poor prognosis</article-title><source>Eur J Haematol</source><year>2009</year><volume>83</volume><fpage>22</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">19245531</pub-id></mixed-citation></ref><ref id="bib15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thornton</surname><given-names>PD</given-names></name><name><surname>Matutes</surname><given-names>E</given-names></name><name><surname>Bosanquet</surname><given-names>AG</given-names></name><name><surname>Lakhani</surname><given-names>AK</given-names></name><name><surname>Ropner</surname><given-names>JE</given-names></name><name><surname>Joshi</surname><given-names>R</given-names></name><etal/></person-group><article-title>High dose methylprednisolone can induce remissions in CLL patients with p53 abnormalities</article-title><source>Ann Hematol</source><year>2003</year><volume>82</volume><fpage>759</fpage><lpage>765</lpage><pub-id pub-id-type="pmid">14551737</pub-id></mixed-citation></ref></ref-list><sec sec-type="supplementary-material" id="sup1"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="xob1"><label>Supplementary Tables 1&#x02013;4</label><media xmlns:xlink="http://www.w3.org/1999/xlink" mimetype="application" mime-subtype="pdf" xlink:href="leu2012209x1.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></back><floats-group><fig id="fig1"><label>Figure 1</label><caption><p>(<bold>a</bold>) OS from second randomization by TRAC-assay-guided (hashed line) vs protocol-guided arm (solid line). (<bold>b</bold>) OS by <italic>in vitro</italic> sensitivity to the given second-line treatment (sensitive=solid line, intermediate=hashed line, resistant=hashed/dotted line). (<bold>c</bold>) OS from first randomization by <italic>in vitro</italic> sensitivity to the randomized treatment (sensitive=solid line, intermediate=hashed line, resistant=hashed/dotted line).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="leu2012209f1"/></fig><table-wrap id="tbl1"><label>Table 1</label><caption><title>Cox regression analyses for LC<sub>90</sub> TRAC assay results<xref ref-type="fn" rid="t1-fn2">a</xref> at trial entry</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="center"/><col align="char" char="("/><col align="char" char="."/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"><italic>Variable</italic></th><th align="center" valign="top" charoff="50"><italic>Events</italic>/<italic>Patients</italic></th><th align="center" valign="top" char="(" charoff="50"><italic>HR and 95&#x00025; confidence interval</italic></th><th align="center" valign="top" char="." charoff="50">P-<italic>value</italic></th></tr></thead><tbody valign="top"><tr><td colspan="4" align="left" valign="top" charoff="50"><italic>OS</italic>&#x02014;<italic>univariate analysis</italic><xref ref-type="fn" rid="t1-fn3">b</xref><xref ref-type="fn" rid="t1-fn4">c</xref></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Log<sub>10</sub> LC<sub>90</sub>-flu</td><td align="center" valign="top" charoff="50">356/544</td><td align="char" valign="top" char="(" charoff="50">1.35 (1.15&#x02212;1.58)</td><td align="char" valign="top" char="." charoff="50">0.0003</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Log<sub>10</sub> LC<sub>90</sub>-chl</td><td align="center" valign="top" charoff="50">355/543</td><td align="char" valign="top" char="(" charoff="50">3.16 (2.25&#x02212;4.44)</td><td align="char" valign="top" char="." charoff="50">&#x0003c;0.0001</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Log<sub>10</sub> LC<sub>90</sub>-maf</td><td align="center" valign="top" charoff="50">354/536</td><td align="char" valign="top" char="(" charoff="50">1.82 (1.25&#x02212;2.65)</td><td align="char" valign="top" char="." charoff="50">0.002</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" char="(" charoff="50">&#x000a0;</td><td align="center" valign="top" char="." charoff="50">&#x000a0;</td></tr><tr><td colspan="4" align="left" valign="top" charoff="50"><italic>PFS</italic>&#x02014;<italic>univariate analysis</italic><xref ref-type="fn" rid="t1-fn3">b</xref></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Log<sub>10</sub> LC<sub>90</sub>-flu</td><td align="center" valign="top" charoff="50">500/ 544</td><td align="char" valign="top" char="(" charoff="50">1.65 (1.42&#x02212;1.91)</td><td align="char" valign="top" char="." charoff="50">&#x0003c;0.0001</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Log<sub>10</sub> LC<sub>90</sub>-chl</td><td align="center" valign="top" charoff="50">499/ 543</td><td align="char" valign="top" char="(" charoff="50">2.48 (1.86&#x02212;3.32)</td><td align="char" valign="top" char="." charoff="50">&#x0003c;0.0001</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Log<sub>10</sub> LC<sub>90</sub>-maf</td><td align="center" valign="top" charoff="50">493/ 536</td><td align="char" valign="top" char="(" charoff="50">1.65 (1.19&#x02212;2.48)</td><td align="char" valign="top" char="." charoff="50">0.003</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" char="(" charoff="50">&#x000a0;</td><td align="center" valign="top" char="." charoff="50">&#x000a0;</td></tr><tr><td colspan="4" align="left" valign="top" charoff="50"><italic>PFS</italic>&#x02014;<italic>multivariate analysis</italic><xref ref-type="fn" rid="t1-fn6">e</xref>&#x0000a;<italic>Addition of LC<sub>90</sub>-flu to model with other known prognostic factors (excluding del17p)</italic><xref ref-type="fn" rid="t1-fn5">d</xref></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;<italic>Treatment</italic></td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" char="(" charoff="50">&#x000a0;</td><td align="center" valign="top" char="." charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;&#x02003;Flu</td><td align="center" valign="top" charoff="50">261/ 284</td><td align="center" valign="top" char="(" charoff="50">1.00</td><td align="char" valign="top" char="." charoff="50">&#x0003c;0.0001</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;&#x02003;Chl</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">1.30 (0.97&#x02212;1.74)</td><td align="center" valign="top" char="." charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;&#x02003;Flu with cyclophosphamide</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">0.53 (0.38&#x02212;0.75)</td><td align="center" valign="top" char="." charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" char="(" charoff="50">&#x000a0;</td><td align="center" valign="top" char="." charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;11q deletion</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">1.53 (1.14&#x02212;2.05)</td><td align="char" valign="top" char="." charoff="50">0.005</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;&#x003b2;2 microglobulin &#x02a7e;4&#x02009;mg/l</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">1.35 (1.06&#x02212;1.74)</td><td align="char" valign="top" char="." charoff="50">0.02</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;<italic>IGHV</italic> unmutated and/or <italic>V3-21</italic> usage</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">2.03 (1.54&#x02212;2.68)</td><td align="char" valign="top" char="." charoff="50">&#x0003c;0.0001</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Log<sub>10</sub> LC<sub>90</sub>-flu</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">1.50 (1.17&#x02212;1.93)</td><td align="char" valign="top" char="." charoff="50">0.002</td></tr></tbody></table><table-wrap-foot><fn id="t1-fn1"><p>Abbreviations: chl, chlorambucil; flu, fludarabine; HR, hazard ratio; maf, mafosfamide; OS, overall survival; PFS, progression-free survival; TRAC, tumor response to anti-neoplastic compounds.</p></fn><fn id="t1-fn2"><label>a</label><p>LC90 values modeled instead of TRAC categories as definitions of both TRAC resistance and PFS use response.</p></fn><fn id="t1-fn3"><label>b</label><p>HR for LC<sub>90</sub> results are for a unit increase.</p></fn><fn id="t1-fn4"><label>c</label><p>None of the LC<sub>90</sub> values retained significance in multivariate analysis for OS.</p></fn><fn id="t1-fn5"><label>d</label><p>LC<sub>90-</sub>chl and LC<sub>90</sub>-maf were not significant after the inclusion of these factors and so have been removed from the model.</p></fn><fn id="t1-fn6"><label>e</label><p>Multivariate analyses tested whether the TRAC assay results added value to the previously identified prognostic factors,<sup><xref ref-type="bibr" rid="bib5">5</xref></sup> with models fitted both with and without the inclusion of the TRAC assay to the baseline models, and the change in deviance examined between the two models. Final model presented in table.</p></fn></table-wrap-foot></table-wrap></floats-group></article>